Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of CKD-519 New Formulation in Healthy Males
NCT02623868Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rocacetrapib in dyslipidemia (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration at 144 hours, Time to Maximum Plasma Concentration at 144 hours and 9 more. Started Oct 2015; status: completed.
02
Drugs
rocacetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02623868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623868.